HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BLCO

Bausch + Lomb Corporation (NYSE)

Healthcare — Medical Instruments & Supplies

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Buy 2.5 / 5 12 analysts
$16.55
$-0.01 (-0.06%)
Target: $17.88 (8.0%)
Sign in to add BLCO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$5.90B
P/E Ratio (TTM)-
Forward P/E15.38
EPS (TTM)$-0.62
Dividend Yield-
Profit Margin-4.21%
Revenue Growth9.40%
ROE-3.28%
Debt/Equity78.58
Recommendation Buy 2.5
Analyst Target$17.88
Analysts12
Indexes NYSE

Technical Indicators

RSI (14)77.9
Beta0.58
SMA 20-
SMA 40-
52-Week High$18.92
52-Week Low$13.09
50-Day Avg$15.74
200-Day Avg$16.17
Avg Volume443.9K
Volume399.2K

Performance Analysis

NEUTRAL

BLCO presents a mixed picture with both positive and negative indicators.

~ Trading at 59% of its 52-week range.
- RSI at 77.9 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 9.4% year-over-year.
- Operating at a loss with -4.2% margin.
+ Wall Street consensus is "Buy" from 12 analysts.
+ Average analyst target of $17.88 implies 8.0% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:00 UTC

Back to Screener Export Report